Swiss National Bank lowered its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 7.6% in the second quarter, Holdings Channel reports. The firm owned 186,000 shares of the specialty pharmaceutical company’s stock after selling 15,300 shares during the period. Swiss National Bank’s holdings in Jazz Pharmaceuticals were worth $26,516,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. State Board of Administration of Florida Retirement System grew its holdings in Jazz Pharmaceuticals by 4.2% during the first quarter. State Board of Administration of Florida Retirement System now owns 73,439 shares of the specialty pharmaceutical company’s stock valued at $10,498,000 after purchasing an additional 2,974 shares during the period. Envestnet Asset Management Inc. grew its holdings in Jazz Pharmaceuticals by 16.8% during the first quarter. Envestnet Asset Management Inc. now owns 45,261 shares of the specialty pharmaceutical company’s stock valued at $6,470,000 after purchasing an additional 6,496 shares during the period. CENTRAL TRUST Co grew its holdings in Jazz Pharmaceuticals by 256.4% during the second quarter. CENTRAL TRUST Co now owns 1,522 shares of the specialty pharmaceutical company’s stock valued at $210,000 after purchasing an additional 1,095 shares during the period. LSV Asset Management grew its holdings in Jazz Pharmaceuticals by 31.0% during the first quarter. LSV Asset Management now owns 1,001,650 shares of the specialty pharmaceutical company’s stock valued at $143,185,000 after purchasing an additional 237,190 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Jazz Pharmaceuticals by 16.5% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 111,430 shares of the specialty pharmaceutical company’s stock valued at $15,929,000 after purchasing an additional 15,821 shares during the period. Hedge funds and other institutional investors own 90.30% of the company’s stock.

Shares of JAZZ opened at $133.03 on Thursday. The firm’s 50 day moving average price is $137.47 and its two-hundred day moving average price is $134.63. The company has a debt-to-equity ratio of 0.58, a quick ratio of 3.52 and a current ratio of 3.71. The firm has a market cap of $7.69 billion, a P/E ratio of 10.87, a PEG ratio of 1.12 and a beta of 1.14. Jazz Pharmaceuticals PLC has a twelve month low of $113.52 and a twelve month high of $174.23.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 EPS for the quarter, topping the Zacks’ consensus estimate of $3.16 by $0.49. The business had revenue of $534.13 million for the quarter, compared to analyst estimates of $507.23 million. Jazz Pharmaceuticals had a net margin of 32.99% and a return on equity of 27.72%. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.49 earnings per share. On average, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 13.44 earnings per share for the current fiscal year.

A number of research analysts have weighed in on the stock. HC Wainwright reaffirmed a “hold” rating and issued a $147.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 8th. Barclays lifted their price target on shares of Jazz Pharmaceuticals from $164.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Piper Jaffray Companies lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price target for the company from $205.00 to $142.00 in a research note on Wednesday. Oppenheimer set a $176.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, July 8th. Finally, ValuEngine raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 8th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $169.86.

In other news, Director Catherine A. Sohn sold 726 shares of the business’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $135.65, for a total value of $98,481.90. Following the sale, the director now owns 9,574 shares of the company’s stock, valued at $1,298,713.10. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Paul Treacy sold 4,371 shares of the business’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $137.40, for a total transaction of $600,575.40. The disclosure for this sale can be found here. Insiders own 4.30% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: Municipal Bonds

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.